Trial Profile
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 May 2023
Price :
$35
*
At a glance
- Drugs OBI 3424 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors OBI Pharma
- 12 May 2023 Results assessing safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors published in the British Journal of Cancer
- 12 Apr 2023 Planned End Date changed from 30 Apr 2024 to 31 Dec 2024.
- 12 Apr 2023 Planned primary completion date changed from 29 Feb 2024 to 31 Dec 2024.